Categories
Pharmaceutical

Demand for Fluorescent In Situ Hybridization (FISH) Tests for Melanoma Cancer Is Expected to Expand at a CAGR of 4.7% Over The Forecast Period

The growth of the market is steady in countries/regions with higher prevalence of melanoma. Spending on advanced and safe melanoma cancer diagnostics is growing in the US, as efforts to diagnose the disease at an early stage gain traction. The American Academy of Dermatology estimates around 9,500 people in the US are diagnosed with skin cancer and more than 1 million people in the US are living with melanoma. With skin cancer as most common form of cancer in the US, an increasing number of people are receiving skin cancer diagnosis every year compared to other type of cancers.

Extensive usage of tanning beds is also leading to the rise in melanoma cancer rates globally. Researchers have also found that UV light from sun and tanning beds not only causes melanoma but increases the risk of benign mole which can progress to melanoma. Europe also shows potential for expansion in melanoma cancer diagnostics owing to the treatment rates, government initiatives supporting diagnosis and treatment, and availability of premium drugs.

Request a report sample to gain comprehensive market insights at

Fluorescent In Situ Hybridization (FISH) Emerging Highly Preferred Test Type

High sensitivity, specificity and speed at which assays can be performed is resulting in significant use of Fluorescent In Situ Hybridization (FISH) test in both research and diagnosis of skin cancer and solid tumors. Fact.MR expects FISH Test to witness steady growth, exceeding US$ 300 million in 2018.

FISH is offering identification of genetic changes that are too small to be visible under microscope. Moreover, FISH test is not required to be performed on the cells actively dividing making it faster than other types of test. With an emphasis on early detection of skin cancer, FISH is becoming a vital tool to detect cancer. FISH is also witnessing significant adoption in detecting melanoma cancer diagnosis compared to Comparative Genomic Hybridization (CGH) Tests, owing to the technical limitations in CGH.

With a significant rise in melanoma cancer, diagnosis is becoming challenging, particularly in case of thin, small, and early-stage melanoma. The biopsy of lesion is performed largely at pathology laboratories to detect melanoma owing to the need for accurate results in early-stage. Majority of the skin biopsy samples are tested at pathology laboratory owing to the availability of advanced tools, microscopes, and special stains to make correct diagnosis.

Get Customization on this Research Report for specific research solutions:

https://www.factmr.com/connectus/sample?flag=RC&rep_id=57

melanoma cancer diagnostics market drivers and restraints impact analysi...

Key Inclusion in this Report

Melanoma Cancer Diagnostics Pricing Analysis by Test Type
Melanoma Cancer Country Wise Epidemiology
Regulation and Reimbursement Scenario
Melanoma Skin Cancer: Global Overview
Melanoma Skin Cancer: Survival Rates
Melanoma Skin Cancer: Higher Risk Countries Across Globe

Global Melanoma Cancer Diagnostics Market Segmentation

Global Melanoma Cancer Diagnostics Market Analysis and Forecast, By Test Type

Fluorescent In Situ Hybridization (FISH) Tests
Comparative Genomic Hybridization (CGH) Tests
Immunohistochemical (IHC) Tests

Global Melanoma Cancer Diagnostics Market Size Analysis By End User

Hospitals
Pathology Laboratories
Cancer Research Centres

Get detailed COVID-19 impact analysis on the Melanoma Cancer Diagnostics Market:

https://www.factmr.com/checkout/57

Key Country-wise Inclusions

• US Melanoma Cancer Diagnostics Market
• Canada Melanoma Cancer Diagnostics Sales
• Germany Melanoma Cancer Diagnostics Market
• UK Melanoma Cancer Diagnostics Industry
• France Melanoma Cancer Diagnostics Market
• Japan Melanoma Cancer Diagnostics Industry

Additional Questions Answered

The report along with the valuable insights on the melanoma cancer diagnostics market provides answers to some of the important questions on melanoma cancer diagnostics market.

Which test type is expected to register the highest growth in the melanoma cancer diagnostics market?
What will be the market share of Cancer research Centers in melanoma cancer diagnostics market?
Which region is likely to remain lucrative in the melanoma cancer diagnostics market?
What factors are driving the growth in the melanoma cancer diagnostics market?

Explore Fact.MR’s Coverage on the Healthcare Domain

Laser Cancer Therapy Market: A recent study by Fact.MR on the Laser Cancer Therapy Market offers a 5-year forecast analysis for the period 2017 – 2022. The study analyzes key trends that are currently influencing the growth of the market. This report covers key dynamics, including drivers, restraints, and opportunities for leading market players along with key stakeholders and emerging players.

Cancer Immunotherapy Market: Fact.MR’s extensive coverage of the Cancer Immunotherapy Market offers in-depth insights into the prominent growth dynamics that are likely to aid the expansion of growth prospects in the near future. Data has been presented in the form of key segments across prominent geographies, along with important information concerning key manufacturers operating within the industry.

Hyperthermia Cancer Treatment Market: The Hyperthermia Cancer Treatment Market study published by Fact.MR offers an unbiased analysis of the prominent drivers, opportunities, and trends expected to shape future expansion outlooks. The report provides a comprehensive assessment of the prominent segments and geographies which are likely to benefit market players in the forthcoming years.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com